image
Healthcare - Biotechnology - NASDAQ - US
$ 2.32
2.28 %
$ 139 M
Market Cap
-2.38
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one ALDX stock under the worst case scenario is HIDDEN Compared to the current market price of 2.32 USD, Aldeyra Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one ALDX stock under the base case scenario is HIDDEN Compared to the current market price of 2.32 USD, Aldeyra Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one ALDX stock under the best case scenario is HIDDEN Compared to the current market price of 2.32 USD, Aldeyra Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ALDX

image
$7.0$7.0$6.0$6.0$5.0$5.0$4.0$4.0$3.0$3.0$2.0$2.0$1.0$1.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
0 REVENUE
0.00%
(60.1) OPERATING INCOME
-140479676.14%
(55.9) NET INCOME
-148768439.98%
(43.2) OPERATING CASH FLOW
-142480163.22%
(44.9) INVESTING CASH FLOW
-149719183.33%
-171 B FINANCING CASH FLOW
-13495357.48%
245 K REVENUE
0.00%
-16.6 M OPERATING INCOME
-2.73%
-15.8 M NET INCOME
-4.60%
-12 M OPERATING CASH FLOW
-50.93%
-1.56 M INVESTING CASH FLOW
-29.72%
7.78 K FINANCING CASH FLOW
103.94%
Balance Sheet Aldeyra Therapeutics, Inc.
image
Current Assets 104
Cash & Short-Term Investments 101
Receivables 0
Other Current Assets 2.92
Non-Current Assets 534 B
Long-Term Investments 0
PP&E 267 B
Other Non-Current Assets 267 B
96.70 %2.79 %Total Assets$104.6t
Current Liabilities 18.6
Accounts Payable 180 K
Short-Term Debt 303 K
Other Current Liabilities 18.6
Non-Current Liabilities 15
Long-Term Debt 0
Other Non-Current Liabilities 15
55.36 %44.64 %Total Liabilities$33.6t
EFFICIENCY
Earnings Waterfall Aldeyra Therapeutics, Inc.
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 60.1
Operating Income (60.1)
Other Expenses (4.27)
Net Income (55.9)
00(10t)(10t)(20t)(20t)(30t)(30t)(40t)(40t)(50t)(50t)(60t)(60t)(70t)(70t)000(60t)(60t)4t(56t)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-78.66% ROE
-78.66%
-53.39% ROA
-53.39%
-69.90% ROIC
-69.90%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Aldeyra Therapeutics, Inc.
image
00(5t)(5t)(10t)(10t)(15t)(15t)(20t)(20t)(25t)(25t)(30t)(30t)(35t)(35t)(40t)(40t)(45t)(45t)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income (55.9)
Depreciation & Amortization 250 K
Capital Expenditures 0
Stock-Based Compensation 7.97
Change in Working Capital 5.91 M
Others 4.67
Free Cash Flow (43.2)
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Aldeyra Therapeutics, Inc.
image
Wall Street analysts predict an average 1-year price target for ALDX of $11 , with forecasts ranging from a low of $10 to a high of $12 .
ALDX Lowest Price Target Wall Street Target
10 USD 331.03%
ALDX Average Price Target Wall Street Target
11 USD 374.14%
ALDX Highest Price Target Wall Street Target
12 USD 417.24%
Price
Max Price Target
Min Price Target
Average Price Target
121210108866442200Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 20
6. Ownership
Insider Ownership Aldeyra Therapeutics, Inc.
image
Sold
0-3 MONTHS
4.83 M USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
127 K USD 2
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX NEW YORK , April 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com - 1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX NEW YORK , April 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com - 1 week ago
ALDX LEGAL NEWS: BFA Law Announces that Aldeyra Therapeutics, Inc. is being Investigated - Contact the Firm if You Lost Money NEW YORK CITY, NY / ACCESS Newswire / April 22, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for potential violations of the federal securities laws. If you invested in Aldeyra Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/aldeyra-therapeutics-inc. accessnewswire.com - 1 week ago
Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the Firm NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against TechTarget, Inc. (NASDAQ:TTGT) and Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided. globenewswire.com - 1 week ago
ALDX Investors Have Opportunity to Join Aldeyra Therapeutics, Inc. Fraud Investigation with the Schall Law Firm LOS ANGELES--(BUSINESS WIRE)--ALDX Investors Have Opportunity to Join Aldeyra Therapeutics, Inc. Fraud Investigation with the Schall Law Firm. businesswire.com - 1 week ago
ALDX LEGAL ALERT: Suffer Losses on Aldeyra Therapeutics, Inc.? Contact BFA Law about Ongoing Investigation NEW YORK CITY, NY / ACCESS Newswire / April 21, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for potential violations of the federal securities laws. If you invested in Aldeyra Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/aldeyra-therapeutics-inc. accessnewswire.com - 1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ: ALDX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. globenewswire.com - 1 week ago
Aldeyra Therapeutics: A Mispriced Gem With Reproxalap's CRL Creating A Golden Buying Opportunity Aldeyra Therapeutics' stock offers a compelling contrarian opportunity, rebounding 70% after a 75% drop due to an FDA CRL for Reproxalap in dry eye disease. The FDA requested additional efficacy data. Aldeyra already has two trials with data expected in Q2 2025, aiming for NDA resubmission by mid-2025. Reproxalap targets upstream inflammation, offering rapid symptom relief in a large market, with a risk-adjusted U.S. revenue potential of $216 million annually. seekingalpha.com - 1 week ago
Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter – Hagens Berman SAN FRANCISCO, April 21, 2025 (GLOBE NEWSWIRE) -- On April 3, 2025 investors in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) saw the price of their shares crash over 70% after the company announced that it received a Complete Response Letter (“CRL”) from the FDA for the resubmission of the New Drug Application (“NDA”) of reproxalap, an investigational drug candidate, for the treatment of dry eye disease. globenewswire.com - 1 week ago
ALDX LEGAL REMINDER: Did Aldeyra Therapeutics, Inc. Commit Securities Violations? Contact BFA Law (NASDAQ:ALDX) NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for potential violations of the federal securities laws. If you invested in Aldeyra Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/aldeyra-therapeutics-inc. globenewswire.com - 1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX NEW YORK CITY, NY / ACCESS Newswire / April 18, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ:ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 1 week ago
ALDX INVESTOR NEWS: Aldeyra Therapeutics, Inc. Investors may be able to Recover Losses in Class Action Investigation -- Contact BFA Law (NASDAQ:ALDX) NEW YORK, April 19, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for potential violations of the federal securities laws. If you invested in Aldeyra Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/aldeyra-therapeutics-inc. globenewswire.com - 1 week ago
8. Profile Summary

Aldeyra Therapeutics, Inc. ALDX

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 139 M
Dividend Yield 0.00%
Description Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Contact 131 Hartwell Avenue, Lexington, MA, 02421 https://www.aldeyra.com
IPO Date May 2, 2014
Employees 9
Officers Laura Nichols Operations Manager Dr. Stephen G. Machatha Ph.D. Chief Development Officer Dr. Todd C. Brady M.D., Ph.D. Chief Executive Officer, President & Director David Burke Head of Investor Relations Mr. Michael Alfieri Head of Finance and Principal Financial & Accounting Officer